Nyxoah received the CE Mark for its Genio system, a disruptive neurostimulator intended to treat obstructive sleep apnea (OSA).
The device offers an alternative method of therapy for OSA, which is estimated to affect nearly a billion people and is the most common sleep disordered breathing condition.
The battery-free, minimally invasive device delivers nerve stimulation for moderate to severe OSA patients who have not had success with positive airway pressure therapy.
